Skyclarys
Biogen cuts jobs at Reata after $2.95 billion deal for kidney drug rights
Anika Sharma
A mere fortnight after the completion of Biogen’s acquisition of Reata Pharmaceuticals, the newly merged entity is taking a scalpel ...
Biogen Buys Reata and Skyclarys for $7.3B, Cuts Jobs
SG Tylor
During a quarterly earnings call, Biogen CEO Chris Viehbacher unexpectedly mentioned that the company had around $7.3 billion in cash. ...
Reata Pharmaceuticals Begins Launching Its First Commercial Product Skyclarys with Approved Supplement
SG Tylor
Source – Reata Pharmaceuticals After receiving approval in the spring, Reata Pharmaceuticals has been eagerly awaiting the launch of its ...
